Monte Rosa Therapeutics (GLUE) Current Deferred Revenue: 2023-2025
Historic Current Deferred Revenue for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to $111.9 million.
- Monte Rosa Therapeutics' Current Deferred Revenue rose 345.67% to $111.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.9 million, marking a year-over-year increase of 345.67%. This contributed to the annual value of $117.2 million for FY2024, which is 262.69% up from last year.
- As of Q3 2025, Monte Rosa Therapeutics' Current Deferred Revenue stood at $111.9 million, which was up 507.79% from $18.4 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Current Deferred Revenue registered a high of $117.2 million during Q4 2024, and its lowest value of $18.4 million during Q2 2025.
- Moreover, its 3-year median value for Current Deferred Revenue was $32.4 million (2023), whereas its average is $50.0 million.
- The largest annual percentage gain for Monte Rosa Therapeutics' Current Deferred Revenue in the last 5 years was 345.67% (2025), contrasted with its biggest fall of 45.20% (2025).
- Monte Rosa Therapeutics' Current Deferred Revenue (Quarterly) stood at $32.3 million in 2023, then skyrocketed by 262.69% to $117.2 million in 2024, then spiked by 345.67% to $111.9 million in 2025.
- Its Current Deferred Revenue stands at $111.9 million for Q3 2025, versus $18.4 million for Q2 2025 and $32.6 million for Q1 2025.